Jinsai Shang

This study identifies FXR as a suppressor of pulmonary fibrosis by interacting with PPP1CB to reduce SMAD2/3 phosphorylation, showing therapeutic potential with TERN101.

This paper introduces GZL626, a novel AR degrader that targets the N-terminal domain and RNF213-UBE2J2 complex, effectively degrading AR and AR-V7 and showing antitumor and antiviral activity.

This paper presents cryo-EM structures of human FATP2, revealing its fatty acid uptake mechanism and drug inhibition strategies.

The paper investigates how covalent inhibitors of PPARγ shift its conformational state, affecting ligand binding and inhibitor efficacy.

This study identifies HGS as a host factor critical for coronavirus infection and discovers RTB as a broad-spectrum antiviral by disrupting HGS-M protein interaction.

This study identifies a PPARγ ligand series that shifts the receptor's conformational ensemble between active and repressive states, revealing how subtle chemical changes influence its function.

The paper identifies a potent orally bioavailable SARS-CoV-2 PLpro inhibitor with in vitro and in vivo antiviral activity against SARS-CoV-2 and related coronaviruses.

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.

This study reveals that covalent PPARgamma inhibitors like GW9662 and T0070907 weaken but do not block binding of other synthetic ligands through an allosteric mechanism, altering the receptor's conformation and ligand binding affinity.

The paper resolves conflicting findings on heme's role in REV-ERBβ-NCoR binding by showing heme directly enhances their interaction through structural and biochemical analyses.